Breaking News, Collaborations & Alliances

SillaJen and ABL Europe Expand Collaboration

ABL will now also provide development, manufacturing, and QC release testing services for SillaJen

SillaJen and ABL Europe have expanded their strategic manufacturing collaboration. Under the current agreement, ABL is currently manufacturing Pexa-Vec (formerly JX-594) for SillaJen’s multinational, randomized Phase 3, open-label study of Pexa-Vec in patients with advanced liver cancer. Under the expanded agreement, ABL will also provide development, manufacturing & QC release testing services for SillaJen’s pipeline product, JX-970.      “Based on SillaJen’s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters